Amplitude Modulated Radiofrequency Electromagnetic Field Treatment Combined With Radiochemotherapy and Maintenance Chemotherapy in Patients With Glioblastoma (Brain-RF)

This study tests whether adding an amplitude-modulated radiofrequency electromagnetic field treatment device to the standard glioblastoma treatment (surgery + chemotherapy + radiation) can improve outcomes for people with newly diagnosed glioblastoma, a highly aggressive brain tumor. The device delivers targeted electromagnetic energy non-invasively. **You may be eligible if...** - You are between 18 and 70 years old - You have been newly diagnosed with glioblastoma confirmed by biopsy/pathology - You had surgery that removed most or all of the tumor (subtotal or gross total resection) - Your MGMT gene promoter is methylated (a molecular marker tested by pathology) - Your overall health is good (WHO performance status 0, 1, or 2) - Your blood counts, kidney, and liver function meet required levels **You may NOT be eligible if...** - You have a brain tumor other than glioblastoma - Your MGMT promoter is not methylated - You did not have surgery, or had only a biopsy - You are outside the 18–70 age range - You have poor organ function Talk to your doctor to see if this trial is right for you.